Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Warrants (Tables)

Warrants (Tables)

6 Months Ended

Jun. 30, 2017

Schedule of Warrants Outstanding and Warrants Activity

Warrants outstanding and warrant activity for the six months ended June 30, 2017 are as follows:

Description	Classification		Exercise Price		Expiration Date	Balance December 31, 2016		Warrants Issued		Warrants Exercised			Balance June 30, 2017
Pre-Funded Warrants, issued June 21, 2017		Liability	$	0.01	None		-		2,600,000		(1,400,000	)		1,200,000
Underwriters Warrants, issued June 21, 2017		Liability	$	1.32	December 2022		-		575,000		-			575,000
Private Placement Warrants, issued January 25, 2017		Equity	$	4.69	June 2022		-		855,000		-			855,000
RedPath Warrants, issued March 22, 2017		Equity	$	4.69	September 2022		-		100,000		-			100,000
Base & Overallotment Warrants, issued June 21, 2017		Equity	$	1.25	June 2022		-		14,375,000		-			14,375,000

							-		18,505,000		(1,400,000	)		17,105,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details